CLOs on the Move

Patheon

www.patheon.com

 
At Patheon, we deliver enhanced simplicity, speed, and quality to clients across the pharmaceutical and biotechnology sectors. As a leading global provider of pharmaceutical development and manufacturing services, we provide a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. With a reputation for scientific and technical excellence, combined with a passion for delivering quality products on time, every time, our approximately 8,700 employees across North America, Europe, Latin America and Australia have enabled Patheon to achieve industry-leading growth. When you ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.patheon.com
  • 4721 Emperor Blvd Ste 200
    Durham, NC USA 27703
  • Phone: 919.226.3200

Executives

Name Title Contact Details
Eric Sherbet
General Counsel Profile

Similar Companies

Kiel Laboratories

Kiel Laboratories, Inc. is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Mar Cor Purification/Fluid Solutions

Mar Cor Purification/Fluid Solutions is a Drexel Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STI Technologies

STI Technologies Limited (STI) is a health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health care products.

Falks Woodland Pharmacy

Falks Woodland Pharmacy is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.